1. Home
  2. RVSN vs MBRX Comparison

RVSN vs MBRX Comparison

Compare RVSN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

N/A

Current Price

$3.54

Market Cap

8.9M

Sector

N/A

ML Signal

N/A

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

N/A

Current Price

$0.57

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RVSN
MBRX
Founded
2016
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.9M
10.1M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
RVSN
MBRX
Price
$3.54
$0.57
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $61.00
AVG Volume (30 Days)
16.5K
★ 1.1M
Earning Date
03-31-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$860.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.16
52 Week High
$9.39
$7.98

Technical Indicators

Market Signals
Indicator
RVSN
MBRX
Relative Strength Index (RSI) 37.26 39.29
Support Level $3.26 $0.16
Resistance Level $5.09 $0.67
Average True Range (ATR) 0.28 0.10
MACD -0.01 0.00
Stochastic Oscillator 31.37 17.47

Price Performance

Historical Comparison
RVSN
MBRX

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: